In April 2024, the FDA banned compounding pharmacies from producing versions of semaglutide (the active ingredient in medications like Ozempic and Wegovy)
As a result of using Defendants Ozempic and Mounjaro, Plaintiff was caused to suffer from severe gastrointestinal events, which resulted in, for example, severe vomiting, stomach pain, gastrointestinal burning, being hospitalized for stomach issues on several occasions, including visits to the emergency room, the lawsuit claims
Mol Psychiatry 30 , 32693300 (2025)
No hubo nada que causara una prdida de peso dramtica
Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: A meta-analysis of randomized clinical trials